Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Reduction. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120758580A reveals enzymatic route for (S)-chiral amines. High ee value, mild conditions. Reliable supplier for pharma intermediates.
Patent CN104450801B details high-yield biocatalysis. Offers supply chain stability and cost reduction for pharmaceutical intermediate manufacturing.
This patent details a safer industrial method for pitavastatin calcium production eliminating cryogenic conditions and reducing costs for reliable supply chain partners.
Patent CN110387359A enables high-purity statin intermediate production via engineered carbonyl reductase mutants ensuring supply chain stability.
Novel enzymatic synthesis for Telotristat ethyl intermediates ensures high purity and scalable supply chain solutions for global pharmaceutical manufacturers seeking cost efficiency.
Patent CN112481226A discloses solvent-tolerant ADH mutants enabling 99.9% conversion for chiral diaryl alcohols, offering a green alternative to costly chemical synthesis.
Patent CN113493814B reveals a one-step enzymatic synthesis of DHEA from androstenedione ester, achieving 94% yield without unstable intermediates.
Novel biocatalytic route for L-carnitine production offers >99% ee, reduced toxicity, and scalable manufacturing for reliable pharmaceutical intermediate supply chains.
Patent CN111433357B reveals high-ee enzymatic reduction for chiral alcohols, offering cost-effective and scalable supply chain solutions for pharmaceutical intermediates.
Patent CN109053479A reveals a green enzymatic route for high-purity Levocarnitine. Discover cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Advanced enzymatic synthesis of levocarnitine via patent CN118879801B offers high yield and supply chain stability for global pharmaceutical manufacturers.
Patent CN103898178A details a high-yield enzymatic route for chiral piperidine alcohols, offering significant cost and purity advantages for API manufacturing.
Patent CN112481226B details solvent-tolerant ADH mutants for scalable production of chiral alcohols, offering significant cost reduction and supply chain reliability for pharma intermediates.
Patent CN104630242B reveals novel biocatalytic routes for chiral intermediates. Enhances supply chain reliability and reduces heavy metal dependency in manufacturing.
Patent CN114686451A discloses amine dehydrogenase mutants for high-yield production. Offers cost reduction in pharma intermediate manufacturing with >99% ee.
Patent CN114350631B reveals a novel NADH-dependent enzyme mutant for L-glufosinate synthesis, offering significant cost reduction and supply chain stability for agrochemical manufacturing.
Patent CN109897872B reveals enzymatic route for HIV intermediate. High conversion and purity ensure reliable pharmaceutical intermediates supplier capability for global procurement.
Patent CN109897872B details enzymatic reduction for HIV inhibitor intermediates. High purity and conversion enable cost reduction and reliable supply chain stability for global manufacturers.
Patent CN118272331B reveals high-efficiency ene reductase mutant for (R)-citronellal. Delivers superior optical purity and scalable biocatalysis for global supply chains.
Patent CN105543186A reveals novel biocatalytic route for high-purity chiral alcohols. Enables cost reduction in chiral alcohol manufacturing and supply chain reliability.